



Obeticholic Acid for Treatment of PBC and NASH

Friday, July 15, 2016 | 10:00AM – 3:30PM
 The Westin Portland Harborview Hotel
 157 High Street, Portland, ME 04101

Agenda

Time	Activity
9:30AM – 10:00AM	Registration
10:00AM – 10:30AM	Meeting Convened and Opening Remarks: <ul style="list-style-type: none"> • Steven Pearson, MD, MSc, President, ICER
10:30AM – 11:45AM	Presentation of the Evidence: <i>PBC clinical effectiveness and value:</i> <ul style="list-style-type: none"> • Reiner Banken, MD, MSc, Senior Fellow, ICER • Jagpreet Chhatwal, PhD, Assistant Professor, Harvard Medical School, MGH Institute for Technology Assessment • Rick Chapman, PhD, MS, Director of Health Economics, ICER <i>NASH clinical effectiveness and value:</i> <ul style="list-style-type: none"> • Reiner Banken, MD, MSc • Jagpreet Chhatwal, PhD • Rick Chapman, PhD, MS
11:45AM-12:30PM	Public Comments and Discussion: <i>Members of the public pre-registered to deliver oral remarks.</i>
12:30PM – 1:00PM	Break for Lunch
1:00PM – 2:00PM	CEPAC Q&A with Clinical Experts CEPAC Deliberation and Votes: <i>ICER staff, along with clinical experts, will be available for questions from the Council during deliberation.</i>
2:00PM – 3:00PM	Policy Roundtable
3:00PM – 3:20PM	New England CEPAC Reflections
3:20PM – 3:30PM	Meeting Adjourned

Participating Members of New England CEPAC

<p>Stacey Brown, PhD Director, Community-based Education Assistant Professor, Community Medicine University of Connecticut School of Medicine</p>	<p>Stephen Kogut, PhD, MBA, RPh Associate Professor, University of Rhode Island College of Pharmacy</p>
<p>Gregory Curfman, MD Editor in Chief, Harvard Health Publications Harvard Medical School</p>	<p>Dora Mills, MD, MPH Vice President for Clinical Affairs, University of New England</p>
<p>Teresa Fama, MD, MS (Chair) Physician, Central Vermont Rheumatology</p>	<p>Stephanie Nichols, PharmD, BCPS, BCPP Associate Professor of Pharmacy Practice, Husson University Psychiatric Pharmacist, Maine Medical Center</p>
<p>Austin Frakt, PhD Health Economist, VA Boston Healthcare System Associate Professor, Boston University School of Public Health Associate Professor, Boston University School of Medicine</p>	<p>Jeanne Ryer, MS Director, New Hampshire Citizens Health Initiative</p>
<p>Claudio Gualtieri, JD Associate State Director of Advocacy, Connecticut AARP</p>	<p>Roger Snow, MD, MPH Former Deputy Medical Director, Medical Policy Commonwealth of Massachusetts, Office of Medicaid</p>
<p>Felix Hernandez, MD, MMM Medical Director, Surgical Services Medical Director, Undergraduate Medical Education Eastern Maine Medical Center</p>	<p>Keith A. Stahl, MD Executive Medical Director, Primary Care and Population Health Catholic Medical Center</p>
<p>Christopher Jones, PhD Assistant Professor, Department of Surgery Director, Global Health Economics Unit Center for Clinical and Translational Science, University of Vermont College of Medicine</p>	<p>Jason Wasfy, MD, MPhil Assistant Medical Director, Massachusetts General Physicians Organization Director of Quality and Analytics, Massachusetts General Hospital Heart Center</p>

**All members of the New England CEPAC meet specified COI standards. COI is defined as: A specific financial association in excess of \$25,000 during the previous year from any one health care manufacturer or insurer; or financial association, such as individual health care stock ownership in excess of \$50,000 in aggregate during the previous year from health care manufacturers or insurers.*

Policy Roundtable

<p>Kathleen Corey, MD, MPH Director, MGH Fatty Liver Clinic Massachusetts General Hospital Gastrointestinal Unit</p>	<p>Juan Carlos Lopez-Talavera, MD, PhD Senior Vice President, Global Medical Affairs Intercept Pharmaceuticals</p>
<p>Judith Donovan* Patient with PBC</p>	<p>Daniel Pratt, MD* Clinical Director, Liver Transplantation; Director, Autoimmune & Cholestatic Liver Center Massachusetts General Hospital</p>
<p>Barbara Henry, RPh Senior Clinical Pharmacy Coordinator Harvard Pilgrim Health Care</p>	<p>Tom Simpatico, MD Chief Medical Officer Vermont Department of Health Access</p>

**No relevant conflicts of interest to disclose, defined as more than \$10,000 in health care company stock or more than \$5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers.*